Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196693 | 0.86 | CACNA1G (0.43) | SIGMAR1SLC6A12TMEM97MCHR1ACHE | |
| SCHEMBL13201163 | 0.86 | CACNA1G (0.43) | SIGMAR1SLC6A12TMEM97MCHR1ACHE | |
| SCHEMBL13196681 | 0.83 | TACR1 (0.48) | SIGMAR1 | |
| SCHEMBL13200970 | 0.83 | TACR1 (0.48) | SIGMAR1 | |
| SCHEMBL6319234 | 0.81 | GRIN2B (0.49) | ALDH1A1GRIN2B | |
| SCHEMBL2801968 | 0.80 | SCN4A (0.43) | SIGMAR1BCHEDRD2DRD4GRIN2B | |
| SCHEMBL2799526 | 0.78 | TACR1 (0.47) | SIGMAR1 | |
| SCHEMBL13200835 | 0.78 | TACR1 (0.47) | SIGMAR1 | |
| SCHEMBL3174670 | 0.74 | FUCA1 (0.47) | SIGMAR1ACHEBCHEBACE1DRD2 | |
| SCHEMBL5988675 | 0.74 | FUCA1 (0.47) | SIGMAR1ACHEBCHEBACE1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
| EP-2170064-A1 | 6.5-PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009002770-A1 | 6.5-PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | SIGMAR1 698/4885SLC6A12 1090/4885TMEM97 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.